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Bach2 is a transcription factor required for affinity maturation of B cells. A recent study reveals, quite
unexpectedly, that Bach2 also plays a key role in the pre-B cell receptor checkpoint and functions as a tumor
suppressor in pre-B cell acute lymphocytic leukemia.From lineage specification to the ultimate
production of plasma cells, the B cell
development program is not only marked
by distinct phases of Ig rearrangement
and diversification, but cell fate decisions
are also often closely coordinated with
the functional status of the surface B cell
receptor (BCR). It is now generally
accepted that B cell development is pro-
grammed with a series of checkpoints
that control the initiation of key down-
stream events. The first major checkpoint,
the pre-B cell receptor (pre-BCR) check-
point, governs the transition from the
pre-BI (completion of VH-DJH rearrange-
ment) to the pre-BII stage (onset of
immunoglobulin [Ig] light chain rearrange-
ment) (Herzog and Jumaa, 2012). Struc-
turally resembling a mature BCR, the
pre-BCR signaling complex is formed
between a productively rearranged Ig
heavy chain (IgH), the invariant, surrogate
light chain, and two accessory signaling
molecules, Iga and Igb. Because VH-DJH
joining carries a great risk of disrupting
the V segment open reading frame, the
pre-BCR checkpoint is believed to func-
tion as a quality control step to monitor
the structural integrity of the newly syn-
thesized IgH chain on a pre-BI cell.
Consequently, cells expressing nonfunc-
tional pre-BCRs are either eliminated
(negative selection) or allowed to rear-
range the second IgH allele if still avail-
able. Cells equipped with a signaling
competent pre-BCR are allowed to
expand and proceed to the pre-BII stage,
where Ig light chain rearrangement is
initiated (positive selection).
Despite its importance in B cell devel-
opment, regulation of the pre-BCR check-
point remains incompletely understood.
First, the transcription factor network
operating at this checkpoint has yet to282 Cancer Cell 24, September 9, 2013 ª201be defined. Second, it is not clear how
signals from the pre-BCR are integrated
into the cell fate decision in a manner
that enables negative selection prior to
positive selection. In a recent Nature
Medicine article, Swaminathan et al.
(2013) made exciting discoveries that
shed light on both fronts. In searching
for novel regulators of the pre-BCR
checkpoint, the investigators honed in
on Bach2 after analyzing relevant gene
expression changes in both humans and
mice.
Bach2 is a transcription factor previ-
ously implicated in Ig class switch recom-
bination and efficient germinal center
formation in mature B cells (Muto et al.,
2004). Two attractive features about
Bach2 were noted. Bach2 was signifi-
cantly upregulated by Pax5 at the onset
of VH-DJH rearrangement. In addition,
the dramatic cell death that results from
Pax5-triggered VH-DJH joining and sub-
sequent negative section was greatly
diminished in Bach2/ pro-B/pre-BI
cells. This was accompanied by reduced
expression of p53 and Arf. Subsequent
chromatin immuneprecipitation (ChIP)
and gene expression analysis revealed
that both Cdkn2a (which encodes Arf)
and Tp53 loci are under reciprocal regula-
tion by Bach2 and Bcl6, a transcriptional
repressor previously shown by the same
group to facilitate positive selection by
suppressing Tp53 (Duy et al., 2011). The
fact that additional genes involved in
checkpoint function were also regulated
by Bach2 and Bcl6 in opposite direc-
tions adds further support to the notion
that the interplay between Bach2 and
Bcl6 coordinates the orderly transition
from negative to positive selection.
Two types of experiments provided the
most definitive proof for a Bach2 require-3 Elsevier Inc.ment in negative selection. First, in a pre-
B differentiation systembased on tyrosine
kinase inhibition (TKI) of BCR-ABL-trans-
formed pre-B cells, Bach2 deficiency
reduced the V(D)J rearrangement effi-
ciency by 20-fold, a defect concurrent
with a similar reduction in the mRNA of
Rag1/2. The notion that Bach2 can
directly regulate Rag1/2 transcription is
supported by several assays including a
Bach2 ChIP of the Rag1 and Rag2 pro-
moters. The second set of experiments,
which included an elegant test of VH-DJH
junction length distribution, showed that
>50% of the Bach2/ precursor B cells
contain nonfunctional VH-DJH joining,
compared to only10% in wild-type con-
trols. Most importantly, reexpression of
Bach2 eliminated nonfunctional IgH re-
arrangements almost completely. Collec-
tively, the results presented by Swamina-
than et al. (2013) have clearly established
Bach2 as a key regulator in the pre-BCR
checkpoint. Mechanistically, these data
are consistent with a model where
Bach2, operating downstream of Pax5,
promotes VH-DJH rearrangement by sus-
taining Rag1/2 expression on the one
hand, and, on the other hand, purges cells
carrying nonfunctional IgH rearrange-
ments through p53-dependent cell death
(Figure 1A).
The secondmajor and novel conclusion
from this study carries significant clinical
implications. Swaminathan et al. (2013)
proposed that BACH2 is a novel tumor
suppressor in pre-B cell acute lympho-
cytic leukemia (pre-B ALL), a notion that
enforces the general concept that pre-B
cell checkpoint regulators often also play
roles in pre-B ALLs. PAX5, BCL6, and
another pre-B cell checkpoint regulator,
SLP-65, have all been previously impli-
cated in pre-B ALLs (Duy et al., 2011;
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Figure 1. Model Illustrating the Cell Fate Outcome Influenced by the Interplay between Bach2 and Bcl6 at the Pre-Bcr Checkpoint and in
Pre-B All
(A) In pre-BI cells, the absence of a functional pre-BCR leaves Bach2 expression at a relatively high level, which eventually triggers p53-dependent apoptosis
when VH-DJH joining has failed on both IgH alleles. This is the proposed mechanism for purging nonfunctional IgH rearrangement from the pre-B cell pool
(bottom). During positive selection, signals transduced from a signaling competent pre-BCR lead to a shift in the Bach2-Bcl6 balance and the subsequent
suppression of Cdkn2a/Tp53 by Bcl6, which is a prerequisite condition for cell survival, expansion, and onset of the Ig light chain rearrangement at the
pre-BII stage (top).
(B) In progenitor B cells, BACH2 expression favors p53 activation, which then imposes a barrier against transformation by aberrantly activated oncogenes
(bottom). In cells where BACH2 expression or activity is reduced by either genetic or epigenetic changes, BCL6 overrides BACH2 influence and suppresses
p53. This shift in the BACH2-BCL6 balance thus impairs the anti-cancer barrier, leading to de novo transformation of pre-B cells or acquisition of therapy
resistance in established pre-B ALLs (top). Dashed arrows indicate it is currently unclear how aberrantly activated oncogenes might activate the BACH2-p53-
apoptosis axis.
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PreviewsHerzog et al., 2006; Mullighan et al.,
2007). The tumor suppressor function of
BACH2 is supported by a large volume
of results from cell culture-based experi-
ments and genetic analysis of mouse
and human pre-B ALLs, as well as clinical
response data of pediatric B-ALL patients
(Swaminathan et al., 2013). The most
striking experiment among many is a
Myc transformation assay performed in
a bone marrow transplantation setting, a
test well-known to evoke the ARF/p53-
enforced tumor suppressive barrier
(Lowe et al., 2004). Consistent with the
ability of Bach2 to antagonize Myc-
induced transformation, Myc-transduced
Bach2/ pre-B cells gave rise to lethal
leukemia within 3 weeks, while recipients
of Myc-transduced, Bach2-proficient
cells remained leukemia-free for up to
10 weeks.
Clinical data from pediatric ALL
patients demonstrated the ability ofBACH2 expression to predict survival
outcome (Swaminathan et al., 2013).
Specifically, at the time of diagnosis,
loss of BACH2 expression strongly
correlated with predicted minimal resid-
ual disease and lower relapse-free sur-
vival. Comparing matched sample pairs
collected at initial diagnosis and sub-
sequent relapse, the authors found loss
of BACH2 expression to be a common
feature of disease relapse. How could
BACH2 expression or function be lost
during pre-B ALL development? The
authors presented four possible sce-
narios, each supported by evidence
from primary human ALL samples. These
include a hot spot mutation in the
BTB domain of BACH2 (found in five
of ten Ph+ ALL cases), promoter
hypermethylation, PAX5 inactivation,
and deletion of 6q15, where the human
BACH2 gene resides. Of note, in three
out of four 6q15 deletion cases examined,Cancer Cell 24, Sthe deletion was an acquired event
at relapse. Combined with a general
reduction of BACH2 mRNA in all
relapsed cases, this observation raises
the distinct possibility that leukemia
subclones with low BACH2 were more
resistant than subclones with higher
BACH2 expression to standard ALL
treatment. This notion is in line with the
differential toxicity of TKI in BCR-ABL-
transformed wild-type and Bach2/
pre-B cells. Because BACH2 and BCL6
play opposing roles in p53 regulation,
checkpoint control, and patient outcome
(Figure 1B), the authors propose to phar-
macologically inhibit BCL6 using the
BCL6 peptide inhibitor RI-BPI (Duy
et al., 2011; Polo et al., 2004) in order to
restore p53 expression and hence thera-
peutic response.
The study by Swaminathan et al. (2013)
raises a number of tantalizing questions.
Is the positive role of Bach2 on p53eptember 9, 2013 ª2013 Elsevier Inc. 283
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Previewsexpression exerted directly at the level of
p53 transcription? Because Bach2 and
Bcl6 recognize distinct DNA binding
sequences, what is the mechanism
underlying their competitive binding
behavior in shared target promoters? In
addition, at least under certain circum-
stances, Bach2 can shuttle between the
cytoplasm and nucleus in a redox sensi-
tive fashion (Chen et al., 2013; Muto
et al., 2002). Therefore, is Bach2 subcellu-
lar localization modulated during the pre-
BCR checkpoint? Since Bach2 has
emerged as a key regulator of the pre-
BCR checkpoint, these issuesmerit future
studies.284 Cancer Cell 24, September 9, 2013 ª201REFERENCES
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The effectiveness of cancer therapeutics targeting signal transduction pathways is comprised of a diversity
of mechanisms that drive de novo or acquired resistance. Two recent studies identify mTOR activation as a
point of convergence of mechanisms that cause resistance to inhibitors of the Raf-MEK-ERK and PI3K
signaling.A critical turning point in the fight against
advanced and metastatic melanomas
occurred just over a decade ago with the
discovery and characterization of the
BRAF activating mutation V600E in about
60% of melanomas (Davies et al., 2002).
This mutation causes constitutive activa-
tion of the B-Raf serine/threonine kinase,
resulting in aberrant and persistent acti-
vation of the Raf-MEK-ERK mitogen-
activated protein kinase cascade. Impor-
tantly, BRAF V600E correlated with poor
prognosis in patients with metastatic mel-
anoma. This prompted the development
and clinical evaluation of Raf and MEK
inhibitors for the treatment of BRAF
mutant metastatic melanoma (Salama
and Flaherty, 2013). The dramatic anti-
tumor activities of these inhibitors led toFood and Drug Administration approval
of two Raf (vemurafenib and dabrafenib)
and one MEK (trametinib) inhibitor for
the treatment of BRAF mutant melanoma
(Chapman et al., 2011; Flaherty et al.,
2012; Hauschild et al., 2012). Despite
the clinical success of these inhibitors,
resistance has limited their long-term clin-
ical impact. Although patient selection
based on BRAF mutation status defines
the patient population that would benefit
from Raf or MEK inhibition, 20%–50% of
patients showed no initial response, sug-
gesting de novo resistance in a significant
subset of melanoma patients (Chapman
et al., 2011; Hauschild et al., 2012).
Furthermore, even for patients who do
respond initially, within three months,
essentially all suffer from relapsed tumorsthat have acquired drug resistance. This
has led to numerous studies that have
identified multiple mechanisms of de
novo and/or acquired resistance to Raf,
inhibition with mechanisms that cause
ERK reactivation downstream of the
inhibitor block, as well as ERK-indepen-
dent mechanisms (Sullivan and Flaherty,
2013).
Corcoran et al. (2013) have recently
identified a mechanism that may provide
a more unifying model for the diverse
mechanisms already identified. Although
decreased phosphorylation of ERK
(pERK) has thus far been the standard
used to gauge tumor sensitivity in both
clinical and preclinical studies, Corcoran
et al. (2013) found that robust inhibition
of pERK was still observed in melanoma
